retatrutide phase 2 obesity trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

In rare cases, severe dehydration caused by prolonged vomiting or diarrhea while taking medications like Ozempic or Wegovy has been linked to acute kidney injury

In HFD-caused hyperlipidemic rats, oat beta-glucan lowered body weight gain inhibits hepatic adipocyte hyperplasia, and decrease epididymal fat pad

These GLP-1 receptor agonists can be categorized as either short-acting compounds, which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compounds (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose

Still, regardless of insurance coverage, most adults who have used GLP-1 drugs said it was difficult to afford them, the KFF poll found

Specifically, moderate to high-intensity aerobic exercise seems to have the strongest effects

Whole grains: Incorporate grains such as quinoa, barley, and whole wheat for fiber-rich, slow-digesting carbohydrates